Boston Medical Sciences has raised $34.8M in Series B funding to push its AI-driven colorectal cancer screening technology forward. The round drew backing from Japan Growth Capital Investment Corporation, Global Brain Corporation, and Beyond Next Ventures Inc.
The company's flagship product, AIM4CRC, is a virtual colonoscopy system built around high-precision virtual bowel cleansing AI and polyp detection AI, designed to allow colon examinations without laxative preparation. Boston Medical Sciences says its goal is to eradicate colorectal cancer deaths worldwide through early detection and prevention.











